- Report
- January 2024
- 200 Pages
Global
From €3990EUR$4,150USD£3,423GBP
- Report
- February 2021
- 360 Pages
United States
From €2308EUR$2,400USD£1,980GBP
- Report
- February 2019
- 105 Pages
Global
From €1240EUR$1,290USD£1,064GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21154EUR$22,000USD£18,147GBP
- Report
- June 2019
- 15 Pages
Global
€9615EUR$10,000USD£8,249GBP
- Report
- June 2019
- 15 Pages
Global
€9615EUR$10,000USD£8,249GBP
- Report
- April 2021
- 64 Pages
Global
€21154EUR$22,000USD£18,147GBP
- Report
- January 2019
- 717 Pages
Global
From €21154EUR$22,000USD£18,147GBP
- Report
- November 2023
- 35 Pages
Global
From €5596EUR$5,820USD£4,801GBP
Complera is a combination antiretroviral medication used to treat HIV/AIDS. It is a fixed-dose combination of three drugs: emtricitabine, rilpivirine, and tenofovir disoproxil fumarate. Complera is used to treat HIV-1 infection in adults and adolescents aged 12 years and older who have not taken antiretroviral medications before. It is also used to replace a current antiretroviral regimen in adults and adolescents aged 12 years and older who are virologically suppressed on a stable antiretroviral regimen for at least six months.
Complera is a part of the larger HIV/AIDS drug market, which includes a variety of antiretroviral medications used to treat HIV/AIDS. These medications are used to reduce the amount of HIV in the body, prevent the virus from replicating, and reduce the risk of HIV-related illnesses.
Some companies in the Complera market include Gilead Sciences, Janssen Pharmaceuticals, and ViiV Healthcare. Show Less Read more
